Welcome Guest
Home » Reports » Antibody Humanization and Affinity Maturation: Services and Platforms, 2017 – 2030

Antibody Humanization and Affinity Maturation: Services and Platforms, 2017 – 2030

Published: Aug 23, 2017
Pages: 224
Product Code: RA10088
License Type :  (Learn More)

First discovered in 1975, monoclonal antibodies are considered to be one of the fastest growing therapy segments in the biopharmaceutical industry. In the year 2016, Humira®, a monoclonal antibody, generated revenues worth more than USD 16 billion to become the highest selling drug. With a strong development pipeline and high clinical success rate, the market continues to witness increasing adoption of antibody based therapies and products.

 

The growing industry has faced / continues to face several challenges. One of the biggest hurdles to the growth of antibody based products has been the lack of technical know-how across different stages of drug discovery. This situation is particularly true for the more traditional pharmaceutical companies that have recently ventured into the targeted therapies domain. Some of these companies have mitigated this issue by making specific acquisitions and / or hiring trained personnel to cater to the requirements. However, several others have preferred to out-source these steps to contract services providers. In fact, over the years, a number of services providers offering antibody discovery have been established, and have grown to become an indispensable part of the biopharmaceutical market.

 

Certain steps of the antibody drug discovery process require advanced expertise, and companies offering these specialized services have attracted significant attention of drug / therapy developers. Two such specific services are to reduce antibody immunogenicity (humanization) and enhance its affinity (affinity maturation). Immunogenicity has continued to be one of the most limiting factors of the clinical success of antibodies. Antibody humanization has emerged as an extensively studied method for reducing antibody immunogenicity. There are several contract services providers that are providing novel technologies beyond the traditional methods to facilitate antibody humanization as well as to enhance antibody affinity. These contract services providers have enabled the drug developers to develop therapeutic antibodies with low immunogenicity and high affinity.

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The “Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030” report provides a comprehensive view on the current landscape and the future outlook of the antibody humanization and affinity maturation contract research services and platforms market. The study presents an in-depth analysis of a diverse set of companies that provide such services across different regions worldwide. In addition to other elements, the report covers the following:

  • The current state of the market with respect to key players along with information on location of these companies, their expertise across antibody humanization and / or affinity maturation, the methodology adopted for providing these services and the revenue / business models used.
  • Elaborate profiles of established / emerging players that have expertise in providing antibody humanization and / or affinity maturation services, highlighting the methodologies adopted by these companies and their recent partnerships and collaborations in the antibody humanization and affinity maturation domain. The profiles also have a detailed future outlook section, detailing the likely strategies that may be adopted by these players to fuel growth in the foreseen future.
  • An analysis of the most active regions in terms of humanization and affinity maturation services for biologics, featuring schematic representations on world maps clearly indicating the location of active services hubs.
  • A benchmark analysis to provide a means to compare existing capabilities within respective peer groups and help stakeholders in the industry to identify ways to achieve a competitive edge over contemporary players.
  • A publication analysis representing recent trends in research on antibody humanization across various academic institutes, highlighting the ongoing innovation in this domain.
  • A SWOT analysis, which elaborates on the strengths, weaknesses, opportunities and threats related to players engaged in this domain.
  • A go-to-guide for outsourcing, representing different models that can be used to facilitate the decision whether companies should out-source a particular activity / operation, or not.

 

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as number of projects being out-sourced, number of projects undertaken per year and expected pricing, we have provided an informed estimate of the likely evolution of the opportunity for antibody humanization and affinity maturation services providers for the period 2017-2030. The base year for the report is 2017. To account for the uncertainties associated with these services and to add robustness to our model, we have provided three forecast scenarios portraying conservative, base and optimistic tracks of the market’s evolution.

 

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These included contributions from Aaron Sato (CSO of LakePharma), Andrew C.R. Martin (Reader in Bioinformatics and Computational Biology at University College London) and Thomas Schirrmann (General Manager of YuMab).

 

 

Example Highlights

  1. Globally, around 60 companies offer antibody humanization and / or affinity maturation services / platforms. Majority of these companies (69%) offer services / platforms for both antibody humanization and affinity maturation.
  2. More than 60% of the services / platforms providers have been established in the last decade alone, indicating that there is significant opportunity in this domain. Of the companies that revealed their revenue model, close to 70% have adopted a fee-for-service model while 15% operate on a shared-risk business model. Platform out-licensing is adopted by the remaining 15% of these companies.
  3. Close to 35% of the companies provide these services for antibodies derived from mice. However, several companies are expanding their services portfolio to provide humanization and affinity maturation services for antibodies derived from other animal models, such as camel, chicken, rabbit and rat.
  4. In terms of the methods used for antibody humanization, around 35% of companies still use traditional CDR grafting approaches for antibody humanization. However, around 10% of stakeholders in the industry currently claim to be using a modified CDR grafting approach. Some of these companies include (indicative list, in alphabetical order) Abzena, AvantGen, ACROBiosystems, BIOTEM, Rx Biosciences, ProteoGenix and WuXi Biologics.
  5. In recent years, various companies have begun to apply novel methods, such as SDR grafting, shotgun mutagenesis and CDR grafting coupled to deimmunization, to carry out antibody humanization. Some of the key players that utilize these methods are (indicative list, in alphabetical order) Abzena, Creative Biolabs, Integral Molecular, LakePharma, Lonza, Syd Labs and Yurogen Biosystems.
  6. Targeted mutagenesis, random mutagenesis and chain shuffling remain the most widely used methods for antibody affinity maturation. These methods are adopted by close to 70% of the affinity maturation services / platforms providers.
  7. The growing preference for these conventional antibody optimization methods has spurred a lot of effort in the advancement of existing humanization and affinity maturation techniques. This trend is reflected in recent publications as well. In fact, more than 34% of the publications on antibody humanization (Oct 2014 - Jun 2017) have highlighted novel humanization techniques other than traditional CDR grafting.
  8. Driven by the growing pipeline of antibody based therapeutics, the demand for contract services providers for drug discovery and optimization is anticipated to increase in the coming years. In terms of the geographical distribution, North America (56%) and Europe (26%) are currently the major hubs for antibody related services. We expect these regions to continue to dominate the market in future as well.

 

 

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information. 

 

 

Chapter Outlines

Chapter 2 provides an executive summary of the report. It offers a high level view on where the antibody humanization and affinity maturation market is headed in the mid to long term.

 

Chapter 3 explains the basics of antibody based therapies, including details on their mechanisms of action and developmental history. The chapter addresses the challenges associated with therapeutic antibodies and gives a historical overview of the methods that have been established to address these challenges. Specifically, the chapter highlights the various techniques that have been employed for reducing antibody immunogenicity (humanization techniques) and enhancing affinity.

 

Chapter 4 includes information on close to 60 companies that offer antibody humanization and / or affinity maturation services. The chapter presents the results of detailed research conducted in this domain, highlighting the presence of various services providers across the world and the rise of new players, information on the most commonly adopted methods for humanization and affinity maturation of antibodies, and specific geographical pockets that have emerged as hubs for such services.

 

Chapter 5 provides comprehensive profiles of some of the established players in this field. Each profile features a detailed technology overview, information on financial performance, expertise in antibody humanization and / or affinity maturation and affiliated recent developments. The profiles also have a detailed future outlook section, highlighting the likely strategies that may be adopted by these players to fuel growth in the foreseen future.

 

Chapter 6 presents profiles of some of the active players in this domain. It highlights the expertise of these players across antibody humanization and affinity maturation. The chapter outlines the various methodologies that the companies have adopted for these services, as well as presents an overview of offerings that the companies provide under these services.

 

Chapter 7 presents a benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies in terms of their expertise across antibody humanization and / or affinity maturation. The analysis allows companies to compare their existing capabilities within and beyond their peer groups, and identify opportunities to become more competitive in the industry. 

 

Chapter 8 provides a publication analysis highlighting the recent trends in published literature on antibody humanization. The chapter provides details on novel methods, as well as the attempts that are being made to modify traditional CDR grafting for antibody humanization.

 

Chapter 9 features an elaborate SWOT analysis, representing the various strengths, weaknesses, opportunities and threats associated with the services providers engaged in this domain.

 

Chapter 10 presents comprehensive projections on how the antibody humanization and affinity maturation services market is likely to grow over the next 10 years. We have segregated the financial opportunity separately for the two services (humanization and affinity maturation) and across different geographies (North America, Europe and Asia). All our predictions are backed by robust analysis of data procured from both secondary and primary sources. Due to uncertainties surrounding some of the assumptions within our forecast model, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.

 

Chapter 11 presents a go-to-guide for outsourcing various steps in the drug discovery and development processes. The chapter presents various models and provides case studies, for each model, in order to clearly outline the decision making process related to out-sourcing.

 

Chapter 12 summarizes the overall report. In this chapter, we provide a recap of the key takeaways from the report, and express our independent opinions related to the research and analysis described in the previous chapters.

 

Chapter 13 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. We have presented the details of interviews held with Aaron Sato (CSO of LakePharma), Andrew C.R. Martin (Reader in Bioinformatics and Computational Biology at University College London) and Thomas Schirrmann (General Manager of YuMab).

 

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

 

Chapter 15 is an appendix, which provides the list of companies and organizations mentioned in the report.

 

 
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Antibody: Historical Background
3.3. Antibody: Structure
3.4. Antibody: Mechanism of Action
3.5. Polyclonal and Monoclonal Antibodies
3.6. Bispecific Antibodies
3.7. Monoclonal Antibodies: A Rapidly Growing Industry
3.7.1. Monoclonal Antibodies: Hurdles and Challenges
3.7.2. Monoclonal Antibodies: Immunogenicity
3.7.2.1. Rational Approaches
3.7.2.1.1. Chimerization
3.7.2.1.2. CDR-Grafting
3.7.2.1.3. Resurfacing
3.7.2.1.4. Superhumanization
3.7.2.1.5. Human String Content Optimization
3.7.2.2. Non-Rational or Empirical Approaches
3.7.2.2.1. Framework Region Library
3.7.2.2.2. Guided Selection
3.7.2.2.3. Framework Region Shuffling
3.7.2.3. Other Methods
3.7.2.3.1. Shotgun Mutagenesis
3.7.2.3.2. Transgenic Animals
3.7.2.4. Monoclonal Antibodies: From Murine to Human
3.7.3. Monoclonal Antibodies: Affinity and Affinity Maturation
3.7.3.1. In Vivo Affinity Maturation
3.7.3.2. In Vitro Affinity Maturation
3.7.3.2.1. Display Technologies
3.7.3.2.2. Other Methods
3.8. Monoclonal Antibodies: Key Enablers
3.9. Monoclonal Antibodies: The Future
 
4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Market Landscape
4.2.1. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Specialization
4.2.2. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Type of Offering
4.2.3. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Year of Establishment and Specialization
4.2.4. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Humanization Method Used
4.2.5. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Affinity Maturation Method Used
4.2.6. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Drug Discovery Expertise
4.2.7. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Geographical Location
4.2.8. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Source Animal
4.2.9. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Business Model
 
4.3. Antibody Humanization and Affinity Maturation Services and Platforms Market: Key Insights
4.3.1. Outsourcing is More Prevalent as Compared to In-house Development
4.3.2. Flexible Service Models are Likely to Attract Drug Developers
4.3.3. Despite the Rise of Fully Human Antibody Generating Platform, the Low Fees and Emergence of Novel Humanization Techniques is Likely to Sustain Interest in this Domain
4.3.4. Humanization and Affinity Maturation Services are Potential Opportunities for Antibody Discovery Services Providers
 
5. COMPANY PROFILES: SERVICES AND PLATFORMS PROVIDERS
5.1. Chapter Overview
5.2. Abzena
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Humanization and Affinity Maturation: Services and Platforms
5.2.3.1. Humanization
5.2.3.2. Affinity Maturation
5.2.4. Recent Developments
5.2.4.1. Collaborations and Partnerships
5.2.4.2. Expansions
5.2.5. Future Outlook
 
5.3. Fusion Antibodies
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Humanization
5.3.4. Recent Developments
5.3.4.1. Collaborations and Partnerships
5.3.5. Future Outlook
 
5.4. GenScript
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Humanization: Services and Platforms
5.4.4. Recent Developments
5.4.5. Future Outlook
 
5.5. Innovative Targeting Solutions
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Humanization and Affinity Maturation: Services and Platforms
5.5.3.1. Humanization
5.5.3.2. Affinity Maturation
5.5.4. Recent Developments
5.5.4.1. Collaborations and Partnerships
5.5.5. Future Outlook
 
5.6. LakePharma
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Humanization and Affinity Maturation: Services and Platforms
5.6.3.1. Humanization
5.6.3.2. Affinity Maturation
5.6.4. Recent Developments
5.6.4.1. Collaborations and Partnerships
5.6.4.2. Expansions
5.6.5. Future Outlook
 
5.7. XOMA
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Humanization and Affinity Maturation: Services and Platforms
5.7.3.1. Humanization
5.7.3.2. Affinity Maturation
5.7.4. Recent Developments
5.7.4.1. Collaborations and Partnerships
5.7.5. Future Outlook
 
6. COMPANY PROFILES: OTHER ACTIVE PLAYERS
6.1. Chapter Overview
6.2. Accurus Biosciences
6.2.1. Company Overview
6.2.2. Platforms and Services Portfolio
6.2.3. Humanization Portfolio
 
6.3. IONTAS
6.3.1. Company Overview
6.3.2. Platforms and Services Portfolio
6.3.3. Affinity Maturation Portfolio
 
6.4. Lonza
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Platforms and Services Portfolio
6.4.4. Humanization Portfolio
 
6.5. Oak BioSciences
6.5.1. Company Overview
6.5.2. Platforms and Services Portfolio
6.5.3. Humanization and Affinity Maturation Portfolio
 
6.6. Panorama Research
6.6.1. Company Overview
6.6.2. Platforms and Services Portfolio
6.6.3. Humanization Portfolio
 
6.7. PX’Therapeutics (Subsidiary of Aguettant)
6.7.1. Company Overview
6.7.2. Platforms and Services Portfolio
6.7.3. Humanization Portfolio
 
6.8. Yurogen Biosystems
6.8.1. Company Overview
6.8.2. Platforms and Services Portfolio
6.8.3. Humanization and Affinity Maturation Portfolio
 
7. BENCHMARK ANALYSIS
7.1. Chapter Overview
7.2. Benchmark Analysis: Methodology
7.3. Benchmark Analysis: Peer Groups
7.3.1. Benchmark Analysis: North America, Peer Group I
7.3.2. Benchmark Analysis: North America, Peer Group II
7.3.3. Benchmark Analysis: North America, Peer Group III
7.3.4. Benchmark Analysis: Europe, Peer Group IV
7.3.5. Benchmark Analysis: Europe, Peer Group V
7.3.6. Benchmark Analysis: Europe, Peer Group VI
7.3.7. Benchmark Analysis: Asia Pacific, Peer Group VII
7.3.8. Benchmark Analysis: Asia Pacific, Peer Group VIII
 
8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Antibody Humanization: Publications
8.2.1. Publication Analysis: Year-wise Trend
8.2.2. Publication Analysis: Key Journals
8.2.3. Publication Analysis: Distribution by Animal Models Used
8.2.4. Publication Analysis: Distribution by Method Used for Humanization
 
9. SWOT ANALYSIS
9.1. Chapter Overview
9.2. Strengths
9.3. Weaknesses
9.4. Opportunities
9.5. Threats
 
10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology
10.3. Antibody Humanization and Affinity Maturation Services Market, 2017-2030
10.4. Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Distribution by Number of Projects
10.5. Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Distribution by Location of Services Providers
10.6. Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Geographical Distribution by Demand
10.7. Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Balance of Trade Analysis
 
11. GUIDE TO OUTSOURCING
11.1. Chapter Overview
11.2. Out- sourcing: The Growing Need
11.3. Out- sourcing: Matrix of Services
11.4. Out- sourcing: The Decision Making Criteria
11.4.1. Cost vs Peripheral Activity Model
11.4.1.1. Case Study I
11.4.2. Transaction Cost Economics Model
11.4.2.1. Case Study II
11.4.3. Cost Assessment Model
11.4.3.1. Case Study III
11.4.4. Out-Sourcing: Decision Tree
11.4.5. Out-Sourcing: Key Parameters for Choosing a Service Provider
 
12. CONCLUSION
12.1. Owing to the Growing Demand for Monoclonal Antibodies, Antibody Discovery Services Providers Have Garnered Significant Interest from Drug Developers
12.2. Despite the Availability of Fully Human Antibody Generating Platforms, the Opportunity for Antibody Humanization Services Providers Remains Largely Unaffected
12.3. CDR-Grafting is the Most Prominent Method for Antibody Humanization; Services Providers are Regularly Improving to Further Enhance the Technique
12.4. North America Spearheads the Market with the Largest Number of Antibody Humanization and Affinity Maturation Services Providers
12.5. Advances in Manufacturing Tools, Availability of Robust Technical Data, and Novel Business Models Indicate Potential Future Growth Opportunities
12.6. Given the Growing Demand for Antibody-based Products, the Contract Services Market is Anticipated to Witness Steady Growth in the Coming Decade
12.7. Concluding Remarks
 
13. INTERVIEW TRANSCRIPTS
13.1. Aaron Sato, Chief Scientific Officer, LakePharma
13.2. Andrew C.R. Martin, Reader in Bioinformatics and Computational Biology, University College London
13.3. Thomas Schirrmann, General Manager, YUMAB
 
14. APPENDIX 1: TABULATED DATA
 
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
 
 
Figure 3.1 Historical Timeline of Antibody Development
 
Figure 3.2 Basic Structure of an Antibody
 
Figure 3.3 Mechanism of Action of Antibodies
 
Figure 3.4 Monoclonal Antibodies: Nomenclature
 
Figure 3.5 Monoclonal Antibodies: Key Facts
 
Figure 3.6 Antibody Humanization: An Approach to Reduce Immunogenicity
 
Figure 3.7 Chimerization: Graphical Representation
 
Figure 3.8 CDR Grafting: Graphical Representation
 
Figure 3.9 Antibody Generation using Transgenic Animals
 
Figure 3.10 Approved Monoclonal Antibodies: Development Trend Analysis
 
Figure 3.11 Affinity Maturation: Display Technologies
 
Figure 3.12 Monoclonal Antibodies Key Enablers: Timeline
 
Figure 3.13 Monoclonal Antibodies in Clinical Trials: Distribution by Type
 
Figure 4.1 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Specialization
 
Figure 4.2 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Type of Offering
 
Figure 4.3 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Year of Establishment and Specialization
 
Figure 4.4 Antibody Humanization and Affinity Maturation Platform and Service Providers: Distribution by Method for Humanization
 
Figure 4.5 Antibody Humanization and Affinity Maturation Platform and Service Providers: Distribution by Method for Affinity Maturation
 
Figure 4.6 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Drug Discovery Expertise
 
Figure 4.7 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Geographical Location
 
Figure 4.8 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Geographical Location and Expertise
 
Figure 4.9 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Geographical Location (North America)
 
Figure 4.10 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Source Animal 
 
Figure 4.11 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Business Model
 
Figure 5.1 Abzena: Operating Segments
 
Figure 5.2 Abzena: Annual Revenues, 2014-H1 2017 (EUR Million)
 
Figure 5.3 Abzena: Affinity Maturation Methodology
 
Figure 5.4 Fusion Antibodies: Services Portfolio
 
Figure 5.5 Fusion Antibodies: CDRx Platform Methodology
 
Figure 5.6 Fusion Antibodies: Antibody Humanization Service Packages
 
Figure 5.7 GenScript: Key Highlights
 
Figure 5.8 GenScript: Annual Revenues, 2012-2016 (USD Million)
 
Figure 5.9 GenScript: Revenues by Business Divisions, 2016 (USD Million)
 
Figure 5.10 GenScript: Humanization Methodology
 
Figure 5.11 HuTARG Platform: Advantages
 
Figure 5.12 Innovative Targeting Solutions: Affinity Maturation Methodology
 
Figure 5.13 LakePharma: Service Portfolio
 
Figure 5.14 LakePharma: Antibody Engineering Services
 
Figure 5.15 LakePharma: Antibody Humanization Methodology
 
Figure 5.16 LakePharma: Affinity Maturation Methodology
 
Figure 5.17 XOMA: Antibody Platforms
 
Figure 5.18 XOMA: Annual Revenues, 2011-2016 (USD Million)
 
Figure 5.19 HE™ Platform: Advantages
 
Figure 5.20 TAE™ Platform: Advantages
 
Figure 6.1 Accurus Biosciences: Service Portfolio
 
Figure 6.2 Accurus Biosciences: Humanization Services Methodology
 
Figure 6.3 IONTAS: Services Portfolio
 
Figure 6.4 IONTAS: Technology Platforms
 
Figure 6.5 Lonza: Annual Revenues, 2012-2016 (CHF Billion)
 
Figure 6.6 Lonza: Development and Manufacturing Services Portfolio
 
Figure 6.7 Lonza: Humanization Services Methodology
 
Figure 6.8 Oak BioSciences: Services Portfolio
 
Figure 6.9 Oak BioSciences: Humanization Service Methodology
 
Figure 6.10 Panorama Research: Services Portfolio
 
Figure 6.11 PX’Therapeutics: Services Portfolio
 
Figure 6.12 PX’Therapeutics: Humanization Service Methodology
 
Figure 6.13 Yurogen Biosystems: Service Segment Overview
 
Figure 6.14 Yurogen Biosystems: Humanization Service Methodology
 
Figure 7.1 Benchmark Analysis: Distribution by Year of Establishment
 
Figure 7.2 Benchmark Analysis: North America, Peer Group I
 
Figure 7.3 Benchmark Analysis: North America, Peer Group II
 
Figure 7.4 Benchmark Analysis: North America, Peer Group III
 
Figure 7.5 Benchmark Analysis: Europe, Peer Group IV
 
Figure 7.6 Benchmark Analysis: Europe, Peer Group V
 
Figure 7.7 Benchmark Analysis: Europe, Peer Group VI
 
Figure 7.8 Benchmark Analysis: Asia Pacific, Peer Group VII
 
Figure 7.9 Benchmark Analysis: Asia Pacific, Peer Group VIII
 
Figure 8.1 Publication Analysis: Quarterly Distribution of Published Articles
 
Figure 8.2 Publication Analysis: Distribution by Key Journals
 
Figure 8.3 Publication Analysis: Distribution by Study Model
 
Figure 8.4 Publication Analysis: Distribution by Method used for Humanization
 
Figure 9.1 Antibody Humanization Services and Platforms Providers: SWOT Analysis
 
Figure 9.2 Antibody Humanization Services and Platforms Providers: Overview of Strengths
 
Figure 9.3 Antibody Humanization Services and Platforms Providers: Overview of Weaknesses
 
Figure 9.4 Antibody Humanization Platform and Service Providers: Overview of Opportunities
 
Figure 9.5 Antibody Humanization Services and Platforms Providers: Overview of Threats
 
Figure 10.1 Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Base Scenario (USD Million)
 
Figure 10.2 Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Distribution by Number of Humanization Projects, Base Scenario
 
Figure 10.3 Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Distribution by Number of Affinity Maturation Projects, Base Scenario
 
Figure 10.4 Antibody Humanization Market, 2017: Distribution by Location of Services Providers
 
Figure 10.5 Antibody Affinity Maturation Market, 2017: Distribution by Location of Service Providers
 
Figure 10.6 Antibody Humanization and Affinity Maturation Market, 2017, 2030: Distribution by Demand
 
Figure 10.7 Antibody Humanization Services Market, 2017: Balance of Trade Analysis
 
Figure 10.8 Antibody Affinity Maturation Services Market, 2017: Balance of Trade Analysis
 
Figure 11.1 R&D Efficiency of Companies: Expenditure vs Drug Approval
 
Figure 11.2 Contract Research Organizations: Types of Services
 
Figure 11.3 Out-sourcing Decision: Transaction Cost Analysis Model
 
Figure 11.4 Out-sourcing Decision: Cost Assessment Model
 
Figure 12.1 Antibody Humanization Market, 2017: Balance of Trade Analysis
 
Figure 12.2 Antibody Humanization and Affinity Maturation Services Market: Conservative, Base and Optimistic Scenarios, 2017-2030 (USD Million)
 
 
Table 3.1 Mechanism of Action of Therapeutic Antibodies against Different Target Classes
 
Table 3.2 Differences between Polyclonal and Monoclonal Antibodies
 
Table 3.3 List of Approved Monoclonal Antibodies
 
Table 3.4 Approved Monoclonal Antibodies: Affinity Overview
 
Table 4.1 Antibody Humanization and Affinity Maturation: Services and Platforms Providers
 
Table 4.2 Antibody Humanization and Affinity Maturation: Description of Services and Platforms Providers
 
Table 5.1 Abzena: Humanization Services Overview
 
Table 5.2 Abzena: Humanized Antibodies in Clinical Development
 
Table 5.3 GenScript: Humanization Service Details
 
Table 5.4 Innovative Targeting Solutions: Drugs in Development
 
Table 5.5 LakePharma: Antibody Humanization Services
 
Table 5.6 LakePharma: Affinity Maturation Services
 
Table 5.7 XOMA: Development Pipeline
 
Table 6.1 Oak BioSciences: Affinity Maturation Services
 
Table 6.2 Panorama Research: Humanization Services
 
Table 6.3 Yurogen Biosystems: Humanization Service Details
 
Table 6.4 Yurogen Biosystems: Affinity Maturation Service Details
 
Table 7.1 Benchmark Analysis: Peer Groups
 
Table 8.1 Antibody Humanization: Publications
 
Table 8.2 Antibody Humanization: Modified CDR Grafting Methods
 
Table 11.1 Out-sourcing Decision: Type of Activity
 
Table 11.2 Out-sourcing Decision: Case Study I
 
Table 14.1 Approved Monoclonal Antibodies: Development Trend Analysis
 
Table 14.2 Monoclonal Antibodies in Clinical Trials: Distribution by Type
 
Table 14.3 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Specialization
 
Table 14.4 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Type of Offering
 
Table 14.5 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Year of Establishment and Specialization
 
Table 14.6 Antibody Humanization and Affinity Maturation Platform and Service Providers: Distribution by Method for Humanization
 
Table 14.7 Antibody Humanization and Affinity Maturation Platform and Service Providers: Distribution by Method for Affinity Maturation
 
Table 14.8 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Drug Discovery Expertise
 
Table 14.9 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Geographical Location
 
Table 14.10 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Geographical Location and Expertise
 
Table 14.11 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Geographical Location (North America)
 
Table 14.12 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Source Animal
 
Table 14.13 Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Business Model
 
Table 14.14 Abzena: Annual Revenues, 2014-H1 2017 (EUR Million)
 
Table 14.15 GenScript: Annual Revenues, 2012-2016 (USD Million)
 
Table 14.16 GenScript: Revenues by Business Divisions, 2016 (USD Million)
 
Table 14.17 XOMA: Annual Revenues, 2011-2016 (USD Million)
 
Table 14.18 Lonza: Annual Revenues, 2012-2016 (CHF Billion)
 
Table 14.19 Benchmark Analysis: Distribution by Year of Establishment
 
Table 14.20 Publication Analysis: Quarterly Distribution of Published Articles
 
Table 14.21 Publication Analysis: Distribution by Key Journals
 
Table 14.22 Publication Analysis: Distribution by Study Model
 
Table 14.23 Publication Analysis: Distribution by Method used for Humanization
 
Table 14.24 Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Base Scenario (USD Million)
 
Table 14.25 Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Optimistic Scenario (USD Million)
 
Table 14.26 Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Conservative Scenario (USD Million)
 
Table 14.27 Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Distribution by Number of Humanization Projects, Base Scenario
 
Table 14.28 Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Distribution by Number of Humanization Projects, Optimistic Scenario
 
Table 14.29 Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Distribution by Number of Humanization Projects, Conservative Scenario
 
Table 14.30 Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Distribution by Number of Affinity Maturation Projects, Base Scenario
 
Table 14.31 Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Distribution by Number of Affinity Maturation Projects, Optimistic Scenario
 
Table 14.32 Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Distribution by Number of Affinity Maturation Projects, Conservative Scenario
 
Table 14.33 Antibody Humanization Market, 2017: Distribution by Location of Services Providers
 
Table 14.34 Antibody Affinity Maturation Market, 2017: Distribution by Location of Service Providers
 
Table 14.35 Antibody Humanization and Affinity Maturation Market, 2017, 2030: Distribution by Demand
 
Table 14.36 Antibody Humanization Services Market, 2017: Balance of Trade Analysis
 
Table 14.37 Antibody Affinity Maturation Services Market, 2017: Balance of Trade Analysis
 
Table 14.38 R&D Efficiency of Companies: Expenditure vs Drug Approval
 
Table 14.39 Antibody Humanization Market, 2017: Balance of Trade Analysis
 
Table 14.40 Antibody Humanization and Affinity Maturation Services Market: Conservative, Base and Optimistic Scenarios, 2017-2030 (USD Million)
 

 

The following companies and organizations have been covered in this report.

 

1. Ab Studio

2. A&G Pharmaceutical

3. Abbott

4. AbbVie

5. Abcam

6. AbCheck

7. Absolute Antibody

8. Abwiz Bio

9. Abzena

10. Abzyme Therapeutics

11. Accurus Biosciences

12. ACROBiosystems

13. Affimed

14. AIMM Therapeutics

15. Akeso Biopharma

16. Alder BioPharmaceuticals

17. Alexion Pharmaceuticals

18. Amgen

19. AnaptysBio

20. Apexigen

21. Aragen Bioscience

22. Aristi Biotech

23. AstraZeneca

24. ATUM

25. AvantGen

26. AxioMx

27. Biogen

28. Bio-Rad

29. BIOTEM

30. Boehringer Ingelheim

31. Bristol-Myers Squibb

32. CAPRA Science Antibodies

33. CARsgen Therapeutics

34. Chugai Pharmaceuticals

35. CisbioCorixa

36. Creative Biolabs

37. Cytogen

38. DaTaMabs

39. Distributed bio

40. Elan Pharma

41. Eli Lilly

42. Elusys Therapeutics

43. ExonBIO

44. Fresenius

45. Fusion Antibodies

46. G&P Biosciences

47. GeneBeyond

48. Genentech

49. Genmab

50. GenScript

51. Genzyme

52. GlaxoSmithKline

53. GlycoNex

54. Henlix Biotech

55. Human Genome Sciences

56. iDD biotech

57. ImClone Systems

58. Immune Biosolutions

59. Immunomedics

60. ImmunoPrecise Antibodies

61. Innate Pharma

62. Innovative Targeting Solutions

63. Integral Molecular

64. IONTAS

65. Janssen Biotech

66. Johnson & Johnson

67. LakePharma

68. Lonza

69. MabPlex

70. MabSpace Biosciences

71. Macromoltek

72. MedImmune

73. Merck

74. MIGS

75. Millennium Pharmaceuticals

76. Mi-mAbs

77. ModiQuest Research

78. Morphotek

79. MRC Technology (LifeArc)

80. NeoRx

81. Noble Life Sciences

82. Novartis

83. Oak Biosciences

84. Organon Teknika

85. Palatin Technologies

86. Panorama Research

87. Pharmaron

88. Precision Antibody

89. ProteoGenix

90. PX'Therapeutics

91. QoolAbs

92. Regeneron Pharmaceuticals

93. Roche

94. Rx Biosciences

95. Sanofi

96. Seattle Genetics

97. Sino Biological

98. Specifica

99. STC Biologics

100. Syd Labs

101. Takeda Pharmaceutical

102. Teva Pharmaceutical

103. Union Chimique Belge

104. United Therapeutics

105. University of Virginia School of Medicine

106. Valeant Pharmaceuticals

107. Viva Biotech

108. Viventia Bio

109. Vrisko

110. WuXi Biologics

111. Wyeth

112. XOMA

113. YUMAB

114. Yurogen Biosystems

115. Zymeworks

 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security